Skip to main content
Dose-adjusted EPOCH and rituximab beneficial for selected older patients with high-risk DLBCL
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Dose-adjusted EPOCH and rituximab beneficial for selected older patients with high-risk DLBCL
User login
Username
Password
Reset your password
Concept
Lead
score
Non-Hodgkin Lymphoma (NHL)
1
1
Antineoplastic Drug
0
0.86
Monoclonal Antibody
0
0.86
Concerns of Elderly
0
0.85
Biologic Therapy
0
0.84
B-Cell Lymphoma
0
1
Lymphoma
0
0.34
Specialty
Lead
score
Hematology-Oncology
1
1
Pharmacist
0
1
Edit Tags